Literature DB >> 1548916

Analysis of 945 cases of pulmonary metastatic melanoma.

D H Harpole1, C M Johnson, W G Wolfe, S L George, H F Seigler.   

Abstract

From 1970 to 1990, 7564 patients with melanoma were seen at Duke University Cancer Center. Complete follow-up data were available in all patients. The estimated probability of a pulmonary metastasis developing 5, 10, or 20 years after initial diagnosis was 0.13, 0.19, and 0.30, respectively. Pulmonary metastases were documented in 945 patients (12%), these having 1-, 3-, and 5-year survival rates of 30%, 9%, and 4%, respectively. The methods of diagnosis were chest radiograph (n = 544), computed tomography (n = 157), transthoracic needle biopsy (n = 121), bronchoscopy (n = 14), thoracotomy (n = 112), and autopsy (n = 7). Evidence of advanced pulmonic spread included bilateral disease in 543 and more than two nodules in 595. Univariate predictors for early formation of pulmonary metastases (p less than 0.001) were male sex, black race, increased primary thickness (millimeters), higher Clark's level, nodular or acral lentiginous histology, location on trunk or head and neck, and regional lymph nodes positive for metastasis. Multivariate predictors of improved survival (p less than 0.001) in order of importance were complete resection of pulmonary disease, longer time for formation of metastases, treatment with chemotherapy, one or two pulmonary nodules, lymph nodes negative for metastasis lymph nodes (p less than 0.005), and histologic type (p less than 0.04). Additionally, survival in patients with one nodule and resection (n = 84) was better than in those with similar disease and no resection (n = 142 months, p less than 0.001). These data comprise the largest series to date and emphasize the importance of long-term follow-up, as well as supporting the selective use of resection for isolated pulmonary metastases, increasing the 5-year survival rate from 4% to 20%.

Entities:  

Mesh:

Year:  1992        PMID: 1548916

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  26 in total

1.  Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I).

Authors:  J Harrison Howard; John F Thompson; Nicola Mozzillo; Omgo E Nieweg; Harald J Hoekstra; Daniel F Roses; Vernon K Sondak; Douglas S Reintgen; Mohammed Kashani-Sabet; Constantine P Karakousis; Brendon J Coventry; William G Kraybill; B Mark Smithers; Robert Elashoff; Stacey L Stern; Alistair J Cochran; Mark B Faries; Donald L Morton
Journal:  Ann Surg Oncol       Date:  2012-05-31       Impact factor: 5.344

2.  Characterization of the frequency distribution for human hematogenous metastases: evidence for clustering and a power variance function.

Authors:  W S Kendal; F J Lagerwaard; O Agboola
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

Review 3.  [Acute emergencies in oncology].

Authors:  D Nashan; S Dengler
Journal:  Hautarzt       Date:  2018-05       Impact factor: 0.751

4.  Editorial on "Growth patterns of pulmonary metastases: should we adjust resection techniques to primary histology and size?"

Authors:  Stefano M M Basso; Sandro C Sulfaro; Paolo Ubiali
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

5.  Thoracic metastasectomy for adoptive immunotherapy of melanoma: a single-institution experience.

Authors:  Jacob A Klapper; Jeremy L Davis; R Taylor Ripley; Franz O Smith; Dao M Nguyen; King F Kwong; Leandro Mercedes; Clinton D Kemp; Aarti Mathur; Donald E White; Mark E Dudley; John R Wunderlich; Steven A Rosenberg; David S Schrump
Journal:  J Thorac Cardiovasc Surg       Date:  2010-07-02       Impact factor: 5.209

Review 6.  Surgical intervention for pulmonary metastases.

Authors:  Joachim Pfannschmidt; Gerlinde Egerer; Marc Bischof; Michael Thomas; Hendrik Dienemann
Journal:  Dtsch Arztebl Int       Date:  2012-10-05       Impact factor: 5.594

Review 7.  Long-term follow-up for melanoma patients: is there any evidence of a benefit?

Authors:  Natasha M Rueth; Kate D Cromwell; Janice N Cormier
Journal:  Surg Oncol Clin N Am       Date:  2015-01-24       Impact factor: 3.495

8.  Essential role for hematopoietic Fas ligand (FasL) in the suppression of melanoma lung metastasis revealed in bone marrow chimeric mice.

Authors:  Christopher L Hall; Mike Yao; Laurie L Hill; Laurie B Owen-Schaub
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

Review 9.  Pulmonary metastasectomy: an overview.

Authors:  Francesco Petrella; Cristina Diotti; Arianna Rimessi; Lorenzo Spaggiari
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

10.  Surgical resection of lung metastases: results from 529 patients.

Authors:  Riad N Younes; Jefferson L Gross; Andrea M Taira; Andrea Aparecida C Martins; Giuliana Sigolo Neves
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.